职称：研究员，博士生导师
主要研究方向：肿瘤免疫逃逸及靶向治疗
个人简介
担任中山大学附属肿瘤医院华南肿瘤学国家重点实验室学术秘书，中国抗癌协会抗癌药物专业委员会委员，广东省抗癌协会抗肿瘤药物专业委员会常务委员兼秘书，广东省药理学会肿瘤药理专业委员常务委员。荣获第十一届中国药理学会“SERVIER青年药理学工作者奖”。于2013年5月到2015年7月在美国MD Anderson Cancer Center乳癌症和肿瘤基础研究中心主任Dr. Mien-Chie Hung实验室从事博士后研究工作。以第一/通讯作者（含共同）发表SCI论文20余篇，包括Nature Cell Biology, Nature Communications（3篇）, Autophagy（2篇）, Molecular Cancer, Signal Transduction and Targeted Therapy, Clinical Cancer Research, Oncogene (3篇) 等国际知名肿瘤学期刊。已获主持包括国家自然科学基金（4项）在内的多项科研基金。申请国家发明专利4项，其中授权3项。
联系方式
电话：020-87342713，020-87343150
电子邮件：dengrong@sysucc.org.cn
地址：广州市东风东路651号 中山大学肿瘤防治中心实验研究部
代表性论著 (# 第一作者；*通讯作者)
(1) Hai-Liang Zhang, Bing-Xin Hu, Zhi-Ling Li, Tian Du, Jia-Lu Shan, Zhi-Peng Ye, Xiao-Dan Peng, Xuan Li, Yun Huang, Xian-Ying Zhu, Yu-Hong Chen, Gong-Kan Feng, Dajun Yang, Rong Deng*, Xiao-Feng Zhu*. PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis. Nature Cell Biology, 2022, 24(1):88-98.
(2) Yan Yu#, Xiao-Dan Peng#, Xiao-Jun Qian#, Kai-Ming Zhang#, Xiang Huang, Yu-Hong Chen, Yun-Tian Li, Gong-Kan Feng, Hai-Liang Zhang, Xue-Lian Xu, Shun Li, Xuan Li, Jia Mai, Zhi-Ling Li, Yun Huang, Dong Yang, Li-Huan Zhou, Zhuo-Yan Zhong, Jun-Dong Li, Rong Deng* and Xiao-Feng Zhu*. Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis. Signal Transduction and Targeted Therapy , 2021, 6(1):401.
(3) Yun Huang#, Hai-Liang Zhang#, Zhi-Ling Li#, Tian Du#, Yu-Hong Chen, Yan Wang, Huan-He Ni, Kai-Ming Zhang, Jia Mai, Bing-Xin Hu, Jun-Hao Huang, Li-Huan Zhou, Dong Yang, Xiao-Dan Peng, Gong-Kan Feng, Jun Tang*, Xiao-Feng Zhu*, and Rong Deng*. FUT8-mediated aberrant N-glycosylation of B7-H3 suppresses the immune response in triple-negative breast cancer. Nature Communnications. 2021,12:2672
(4) Zhi-Ling Li# , Hai-Liang Zhang#, Yun Huang#, Jun-Hao Huang, Peng Sun, Ning-Ning Zhou,Yu-Hong Chen, Jia Mai, Yan Wang, Yan Yu, Li-Huan Zhou, Xuan Li, Dong Yang, Xiao-Dan Peng, Gong-Kan Feng, Jun Tang* , Xiao-Feng Zhu*, Rong Deng*. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nature Communications, 2020, 11:3806.
(5) Xuan Li#, Xiao-Qi Wu#, Rong Deng#, Dan-Dan Li, Jun Tang, Wen-Dan Chen, Jing-Hong Chen, Jiao Ji, Lin Jiao, Shan Jiang, Fen Yang, Gong-Kan Feng, Senthilkumar Ravichandran, Fei Yue, Hai-Liang Zhang, Rui-Yan Wu, Yan Yu, Xue-Lian Xu, Jia Mai, Zhi-Ling Li, Xiao-Dan Peng, Yun Huang, Xiang Huang, Ning-Fang Ma, Qian Tao, Yi-Xin Zeng, Xiao-Feng Zhu*. CaMKII- mediated Beclin 1 phosphorylation regulates autophagy that promotes degradation of Id and neuroblastoma cell differentiation, Nature Communications, 2017, 8(1):1159.
(6) Rong Deng#, Jun-Hao Huang#, Yan Wang#, Li-Huan Zhou#, Zi-Feng Wang, Bing-Xin Hu, Yu-Hong Chen, Dong Yang, Jia Mai, Zhi-Ling Li, Hai-Liang Zhang, Yun Huang, Xiao-Dan Peng, Gong-Kan Feng, Xiao-Feng Zhu1* and Jun Tang* Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma. Molecular Cancer, 2020,8,19(1):122.
(7) Rui-Yan Wu#, Peng-Fei Kong#, Liang-Ping Xia#, Yun Huang#, Zhi-ling Li, Yun-Yun Tang, Yu-Hong Chen, Xuan Li, Senthilkumar Ravichandran, Hai-Liang Zhang, Ting Sun, Xue-Lian Xu, Yan Yu, Jia Mai, Xiao-Dan Peng, Dong Yang, Li-Huan Zhou, Gong-Kan Feng, Rong Deng*, Xiao-Feng Zhu*, Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Clinical Cancer Research, 2019, 25(14): 4530-4541.
(8) Rong Deng#, Hai-Liang Zhang# , Jun-Hao Huang#, Rui-Zhao Cai#, Yan Wang ,Yu-Hong Chen , Bing-Xin Hu , Zhi-Peng Ye, Zhi-Ling Li, Jia Mai , Yun Huang, Xuan Li , Xiao-Dan Peng , Gong-Kan Feng , Jun-Dong Li , Jun Tang*, Xiao-Feng Zhu*. MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis. Autophagy. 2021 Oct;17(10):3011-3029.
(9) Lin Jiao#, Hai-Liang Zhang#, Dan-Dan Li#, Ke-Li Yang, Jun Tang, Xuan Li, Jiao Ji, Yan Yu, Rui-Yan Wu, Ravichandran Senthilkumar, Jian-Jun Liu, Gong-Kan Feng, Min-Shan Chen, Yi-Xin Zeng, Rong Deng*, Xiao-Feng Zhu*, Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2) . Autophagy, 2018, 14(4):671-684.
(10) Jia Mai#, Xiao-Dan Peng#, Jun Tang#, Tian Du, Yu-Hong Chen, Zi-Feng Wang, Hai-Liang Zhang, Jun-Hao Huang, Zhuo-Yan Zhong, Dong Yang, Zhi-Ling Li, Yun Huang, Gong-Kan Feng, Xiao-Feng Zhu*, and Rong Deng*. AKT-Mediated Regulation of Chromatin ubiquitination and Tumorigenesis through Mel-18 Phosphorylation. Oncogene. 2021,40: 2422-2436.
(11) Deng R#, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX , Zhu XF*. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene. 2011,30: 944-55.
(12) Deng R#, Li W#, Guan Z, Zhou JM, Wang Y, Mei YP, Li MT, Feng GK, Huang W, Liu ZC, Han Y*, Zeng YX, Zhu XF*. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene. 2006,25(53):7070-7.
(13) Rui-Yan Wu#, Caiq-Qin Wang#, Zhi-Ming Li#, Jian Xiao, Chun-Yan Li, Xue-Min Wang, Peng-Fei Kong, Jiang-Hua Cao, Fu-Xue Huang, Zhi-Ling Li, Yun Huang, Yu-Hong Chen, Xuan Li, Dong Yang, Hai-Liang Zhang, Jia Mai, Gong-Kan Feng, Rong Deng*, Xiaofeng Zhu*. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Journal for ImmunoTherapy of Cancer, 2020, 8:e001037.
(14) Jia Mai#, Zhuo-Yan Zhong#, Gui-Fang Guo#, Xiu-Xing Chen, Yan-Qun Xiang, Xuan Li, Hai-Liang Zhang,Yu-Hong Chen, Xue-Lian Xu, Rui-Yan Wu1, Yan Yu1, Zhi-Ling Li, Xiao-Dan Peng, Yun Huang, Li-Huan Zhou, Gong-Kan Feng, Xiang Guo, Rong Deng*, Xiao-Feng Zhu1*. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma. Theranostics, 2019 26,9(12):3541 -3554.
(15) Rong Deng#, Jun Tang, Liang-Ping Xia, Dan-Dan Li, Wen-Jun Zhou, Lin-Lin Wang, Gong-Kan Feng, Yi-Xin Zeng, You-Heng Gao, Xiao-Feng Zhu*. ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Molecular Cancer Therapeutics, 2009, 8(4) :873-882.
(16) Rong Deng#, Jun Tang, Bing-Fen Xie, Gong-Kan Feng, Zong-Chao Liu, Xiao-Feng Zhu*. SYUNZ-16, a new synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. International Journal of Cancer, 2010,127(1):220-9.
更新日期：2022年10月18日
